RecruitingPhase 2NCT05844644

The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes

Studying PLA2G6-associated neurodegeneration

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Golo
Principal Investigator
David Crowley, MD, MD
KGK Science Inc.
Intervention
Release(dietary_supplement)
Enrollment
100 target
Eligibility
18-75 years · All sexes
Timeline
20232025

Study locations (2)

Collaborators

KGK Science Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05844644 on ClinicalTrials.gov

Other trials for PLA2G6-associated neurodegeneration

Additional recruiting or active studies for the same condition.

See all trials for PLA2G6-associated neurodegeneration

← Back to all trials